Pentafluoropentanol CAS 148043-73-6: Your Key Intermediate for Anticancer Drug Synthesis

Discover the critical role of Pentafluoropentanol (CAS 148043-73-6) as a high-purity intermediate for synthesizing vital anticancer drugs like Fulvestrant. As a leading manufacturer and supplier, we offer reliable sourcing and expert support.

Get a Quote & Sample

Why Choose Our Pentafluoropentanol?

Guaranteed Purity & Quality

Our commitment to 98%min purity for Pentafluoropentanol guarantees that your synthesis processes will yield the highest quality pharmaceutical products. As a reliable supplier, we ensure every batch meets stringent quality control standards.

Essential for Anticancer APIs

Pentafluoropentanol is a vital component in the synthesis of critical anticancer agents. By choosing us as your manufacturer, you secure a dependable source for this key pharmaceutical intermediate, streamlining your API production.

Reliable Global Supply Chain

We understand the importance of supply stability. As a China-based manufacturer and supplier, we offer a robust supply chain for Pentafluoropentanol, ensuring you can buy with confidence for your ongoing production needs.

Applications in Pharmaceutical Synthesis

Fulvestrant Synthesis

Pentafluoropentanol is a crucial intermediate in the complex synthesis of Fulvestrant, an important drug for hormone-receptor-positive advanced breast cancer. Trust our supply to facilitate your research and production.

API Manufacturing

As a high-quality organic intermediate, Pentafluoropentanol is indispensable for the manufacturing of Active Pharmaceutical Ingredients (APIs), meeting the rigorous demands of the pharmaceutical industry.

Custom Synthesis Projects

For specific project requirements, we offer custom synthesis services to ensure you receive Pentafluoropentanol tailored to your exact needs, reinforcing our position as a flexible supplier.

Research & Development

Researchers and formulators can reliably buy Pentafluoropentanol for R&D purposes, leveraging its unique properties for developing next-generation therapeutics.